Drug Profile
Insulin oral - Oramed Pharmaceuticals
Alternative Names: Oral insulin capsule - Oramed; Orally ingestible insulin capsule - Oramed Pharmaceuticals; ORMD-0801Latest Information Update: 06 Nov 2023
Price :
$50
*
At a glance
- Originator Oramed Pharmaceuticals
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preregistration Type 2 diabetes mellitus
- Phase II Non-alcoholic steatohepatitis; Type 1 diabetes mellitus
Most Recent Events
- 02 Oct 2023 Efficacy data and adverse events data from a phase II trial in Type 2 diabetes patients with nonalcoholic steatohepatitis (NASH) presented at 59th Annual Meeting of the European Association for the Study of Diabetes (EASD-2023)
- 03 Aug 2023 Oramed Pharmaceuticals and Hefei Tianhui Incubator of Technologies (HTIT) plans a phase III trial for Type-2 diabetes mellitus in USA
- 15 May 2023 Preregistration for Type 2 diabetes mellitus in China (PO)